Summary (tl;dr)

Breckenridge Pharmaceuticals has issued a significant nationwide recall of its duloxetine delayed-release capsules due to the presence of a potentially cancer-causing impurity, N-nitroso-duloxetine, exceeding acceptable limits. This recall affects nearly 375,000 bottles distributed across the United States.

Essential Background

Duloxetine, also known by the brand name Cymbalta, is a widely prescribed antidepressant used to treat depression, generalized anxiety disorder, fibromyalgia, and various types of chronic pain, including neuropathic pain. Over the past few years, the U.S. Food and Drug Administration (FDA) has been investigating the presence of nitrosamine impurities in various medications, a class of compounds classified as probable human carcinogens. There have been several recalls of duloxetine, including previous actions by Breckenridge Pharmaceuticals and Rising Pharmaceuticals in late 2024 and early 2025, prompted by similar concerns over nitrosamine levels.

The Full Story

The current surge in searches relates to a major voluntary recall initiated by Breckenridge Pharmaceuticals on June 4, 2026. This recall involves approximately 375,000 bottles of both 30 mg and 60 mg duloxetine delayed-release capsules, distributed nationwide. The reason for the recall is the detection of N-nitroso-duloxetine impurity levels above the FDA's acceptable limits. The affected capsules were manufactured by Towa Pharmaceutical Europe, S.L. in Barcelona, Spain. The FDA has classified this as a Class II recall, meaning that exposure to the contaminated product may cause temporary or medically reversible adverse health consequences, with a low likelihood of serious harm. While there have been no reports of adverse effects directly linked to this specific recall, patients are advised not to discontinue their medication abruptly without consulting a healthcare provider, as sudden cessation can lead to withdrawal symptoms.

Why It Matters

This recall is significant because long-term exposure to nitrosamine impurities above acceptable daily intake limits may increase the risk of cancer. Patients who rely on duloxetine for managing depression, anxiety, and chronic pain are directly affected, raising concerns about the safety and efficacy of their medication. The ongoing nature of these recalls highlights a broader industry-wide effort to identify and mitigate nitrosamine impurities in pharmaceuticals, ensuring patient safety. Healthcare providers and pharmacists are urged to check their inventory and guide patients on managing their prescriptions safely.

Geographic Location

• United States (nationwide distribution of recalled product)
• New Jersey, United States (Breckenridge Pharmaceuticals, recalling company)
• Barcelona, Spain (Towa Pharmaceutical Europe, S.L., manufacturing location)